keyword
MENU ▼
Read by QxMD icon Read
search

Cerebrolysin

keyword
https://www.readbyqxmd.com/read/29303438/prospective-randomized-blinded-and-placebo-controlled-study-of-cerebrolysin-dose-response-effects-on-long-term-functional-outcomes-in-a-rat-model-of-mild-traumatic-brain-injury
#1
Yanlu Zhang, Michael Chopp, Zheng Gang Zhang, Yi Zhang, Li Zhang, Mei Lu, Talan Zhang, Stefan Winter, Hemma Brandstätter, Asim Mahmood, Ye Xiong
OBJECTIVE Cerebrolysin is a neuropeptide preparation that mimics the properties of neurotrophic factors and has had beneficial effects in the treatment of neurodegenerative diseases, stroke, and traumatic brain injury (TBI). To further evaluate treatment schemes, the authors assessed the dose-response of Cerebrolysin on functional improvement in a rat model of mild TBI (mTBI). METHODS This dose-response study was a prospective, randomized, blinded, and placebo-controlled preclinical experiment. Male Wistar adult rats, subjected to mTBI induced by a closed head impact, were treated randomly with 0 (saline as placebo), 0...
January 5, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29248999/safety-and-efficacy-of-cerebrolysin-in-early-post-stroke-recovery-a-meta-analysis-of-nine-randomized-clinical-trials
#2
Natan M Bornstein, Alla Guekht, Johannes Vester, Wolf-Dieter Heiss, Eugene Gusev, Volker Hömberg, Volker W Rahlfs, Ovidiu Bajenaru, Bogdan O Popescu, Dafin Muresanu
This meta-analysis combines the results of nine ischemic stroke trials, assessing efficacy of Cerebrolysin on global neurological improvement during early post-stroke period. Cerebrolysin is a parenterally administered neuropeptide preparation approved for treatment of stroke. All included studies had a prospective, randomized, double-blind, placebo-controlled design. The patients were treated with 30-50 ml Cerebrolysin once daily for 10-21 days, with treatment initiation within 72 h after onset of ischemic stroke...
December 16, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/29222803/synthesis-of-biocompatible-titanate-nanofibers-for-effective-delivery-of-neuroprotective-agents
#3
Asya Ozkizilcik, Roger Williams, Z Ryan Tian, Dafin F Muresanu, Aruna Sharma, Hari S Sharma
Nanoscience provides us with new opportunities to develop nanotechnologies for treating, in particular, central nervous system disorders such as Alzheimer disease and multiple sclerosis. From a methodological point of view, it is challenging to deliver drugs effectively across the blood-brain barrier and blood-cerebrospinal fluid barrier. Our 10-year data and reports from both in vivo and in vitro studies, however, have consistently proved that therapeutic drugs of different types can be generally loaded in/on the nanocarriers for targeted and programmable deliveries to the central nervous system with a high degree of efficacy...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29172008/effects-of-cerebrolysin-on-nerve-growth-factor-system-in-the-aging-rat-brain
#4
Mikhail Stepanichev, Mikhail Onufriev, Viktor Aniol, Sofia Freiman, Hemma Brandstaetter, Stefan Winter, Natalia Lazareva, Alla Guekht, Natalia Gulyaeva
BACKGROUND: Aging is associated with some cognitive decline and enhanced risk of development of neurodegenerative diseases. It is assumed that altered metabolism and functions of neurotrophin systems may underlie these age-related functional and structural modifications. CerebrolysinTM (CBL) is a neuropeptide mixture with neurotrophic effects, which is widely used for the treatment of stroke and traumatic brain injury patients. It is also evident that CBL has an overall beneficial effect and a favorable benefit-risk ratio in patients with dementia...
2017: Restorative Neurology and Neuroscience
https://www.readbyqxmd.com/read/29171486/-monitoring-of-neurotrophic-factors-and-cognitive-function-in-patients-with-traumatic-brain-injury
#5
Yu V Karakulova, N V Selyanina
AIM: To study the neurological and cognitive status in comparison to the quantitative content of blood serum neurotrophic factors of patients with acute and long-term brain injury during treatment with cerebrolysin. MATERIAL AND METHODS: Eighty patients, 56 men and 24 women, aged from 18 to 64 years, were examined in acute and long-term periods of the brain injury of moderate severity. An open, comparative, randomized study was performed before and after treatment with cerebrolysin...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29155000/role-of-cerebrolysin-%C3%A2-in-cervical-spondylotic-myelopathy-patients-a-prospective-randomized-study
#6
Ahmad Fouad Abdelbaki Allam, Tarek Abdalla Ahmed Abotakia, Wael Koptan
BACKGROUND CONTEXT: Cerebrolysin(®) is a mixture containing 85% free amino acids and 15% biologically active low-molecular weight peptides, that is believed to mimic the effects of endogenous neurotrophic factors to interact with the pathological process cascade of neurodegenerative diseases. No study has examined the effect of Cerebrolysin(®) on the cervical myelopathic patients. PURPOSE: To evaluate the effect of cerebrolysin(®) as a conservative modality on cervical spondylotic myelopathic patients...
November 14, 2017: Spine Journal: Official Journal of the North American Spine Society
https://www.readbyqxmd.com/read/29142564/clinical-effects-of-ganglioside-and-fructose-1-6-diphosphate-on-neonatal-heart-and-brain-injuries-after-asphyxia
#7
Xiaojing Zhu, Hongya Li, Congmin Zhang
Objective: To study the clinical effect of ganglioside (GM) and fructose-1, 6-diphosphate (FDP) on neonatal heart and brain injuries after asphyxia. Methods: Ninety-one neonates with asphyxia neonatal heart and brain injuries were randomly divided into an observation group and a control group. Both groups were given symptomatic treatment as soon as possible. On this basis, the observation group was given 200 mL of 5% glucose injection and 20 mg of GM and 250 mg/kg·d FDP by intravenous infusion...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29132543/intravenous-administration-of-functionalized-magnetic-iron-oxide-nanoparticles-does-not-induce-cns-injury-in-the-rat-influence-of-spinal-cord-trauma-and-cerebrolysin-treatment
#8
Preeti K Menon, Aruna Sharma, José V Lafuente, Dafin F Muresanu, Zoraida P Aguilar, Y Anderw Wang, Ranjana Patnaik, Herbert Mössler, Hari S Sharma
Influence of iron oxide magnetic nanoparticles (IOMNPs, 10nm in diameter, 0.25 or 0.50mg/mL in 100μL, i.v.) on the blood-brain barrier (BBB) permeability, edema formation, and neuronal or glial changes within 4-24h after administration was examined in normal rats and after a focal spinal cord injury (SCI). Furthermore, effect of cerebrolysin, a balanced composition of several neurotrophic factors, and active peptide fragments was also evaluated on IOMNP-induced changes in central nervous system (CNS) pathology...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/29132541/novel-treatment-strategies-using-tio2-nanowired-delivery-of-histaminergic-drugs-and-antibodies-to-tau-with-cerebrolysin-for-superior-neuroprotection-in-the-pathophysiology-of-alzheimer-s-disease
#9
Aruna Sharma, Preeti K Menon, Ranjana Patnaik, Dafin F Muresanu, José V Lafuente, Z Ryan Tian, Asya Ozkizilcik, Rudy J Castellani, Herbert Mössler, Hari S Sharma
More than 5.5 million Americans of all ages are suffering from Alzheimer's disease (AD) till today for which no suitable therapy has been developed so far. Thus, there is an urgent need to explore novel therapeutic measures to contain brain pathology in AD. The hallmark of AD includes amyloid-beta peptide (AβP) deposition and phosphorylation of tau in AD brain. Recent evidences also suggest a marked decrease in neurotrophic factors in AD. Thus, exogenous supplement of neurotrophic factors could be one of the possible ways for AD therapy...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/29107328/effect-of-cerebrolysin-on-the-cerebellum-of-diabetic-rats-an-imunohistochemical-study
#10
Rania N Sherif
BACKGROUND: Diabetes mellitus represents one of the disorders in the metabolism that affects all body systems including CNS. Cerebrolysin contains many neurotrophic factors, and many studies reported that it can be used treatment of many neurological disorders. AIM OF THE WORK: The aim of the current study was to study the potential neuroprotective effect of cerebrolysin on the cerebellum of diabetic rat. MATERIALS AND METHODS: Sprague Dawley male rats were divided randomly into four groups: control, cerebrolysin (Cbl), diabetes and diabetes treated with Cbl groups...
October 25, 2017: Tissue & Cell
https://www.readbyqxmd.com/read/29075344/efficacy-of-cerebrolysin-in-the-reduction-of-spasticity-during-stroke-rehabilitation
#11
R M Martinez
AIM: This study assessed the efficacy of Cerebrolysin on post-stroke spasticity, motor recovery, and global functions in an outpatient rehabilitation setting. METHODS: In this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection. Control patients did not receive Cerebrolysin. All the patients participated in a standardized physical and occupational rehabilitation therapy for one month at least two times per week...
July 2017: Journal of Medicine and Life
https://www.readbyqxmd.com/read/29075343/efficacy-and-safety-of-cerebrolysin-treatment-in-early-recovery-after-acute-ischemic-stroke-a-randomized-placebo-controlled-double-blinded-multicenter-clinical-trial
#12
K Gharagozli, A A Harandi, S Houshmand, N Akbari, D F Muresanu, J Vester, S Winter, H Moessler
Background and Purpose : The aim of this study was to evaluate the efficacy, safety, and tolerability of cerebrolysin in the early recovery phase after acute ischemic stroke. Methods. This prospective, randomized, double-blinded, placebo-controlled, multicenter, parallel-group study enrolled a total of 100 patients within 18 h after the onset of stroke. The patients were treated with Cerebrolysin (30 mL over seven days followed by 10 mL until day 30) or placebo once daily over a period of four weeks. Efficacy was primarily assessed by the NIH Stroke Scale at day 30, and additional parameters included the modified Rankin Scale, the Clinical Global Impression, the Patient Global Satisfaction (PGS) and the Mini Mental State Examination (MMSE)...
July 2017: Journal of Medicine and Life
https://www.readbyqxmd.com/read/29053124/-the-efficacy-of-cerebrolysin-in-the-treatment-of-autism-spectrum-disorders
#13
L S Chutko, E A Yakovenko, S Yu Surushkina, E M Kryukova, S V Palaieva
AIM: To evaluate clinical and neurophysiological changes in children with different variants of autism spectrum disorders during treatment with cerebrolysin. MATERIAL AND METHODS: Forty-three children with autism spectrum disorders, aged 4-6 years, were included in the study. To assess the degree of autism, the quantitative scale of assessing the severity of child autism CARS ('Childhood Autism Rating Scale') was used. A comparative analysis of the clinical picture of disease and data of the electroencephalographic examination in endogenous and exogenous (organic) variant of autism was made...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28884714/-therapeutic-monitoring-and-prediction-of-the-efficacy-of-neurotrophic-treatment-in-patients-with-amnestic-type-of-mild-cognitive-impairment
#14
S I Gavrilova, O M Volpina, I V Kolykhalov, Ya B Fedorova, N D Selezneva, E V Ponomareva, D O Koroev, A V Kamynina
AIM: To perform therapeutic monitoring and prediction of the neurotrophic therapy efficacy in patients with amnestic type of mild cognitive impairment (aMCI) in a model of course cerebrolysin therapy. MATERIAL AND METHODS: The study involved a group of 19 elderly patients who met the diagnostic criteria of aMCI. All patients received a course of neurotrophic therapy consisting of 20 intravenous infusions of cerebrolysin (30 ml of cerebrolysin in 100 ml of isotonic sodium chloride solution)...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28875428/timed-release-of-cerebrolysin-using-drug-loaded-titanate-nanospheres-reduces-brain-pathology-and-improves-behavioral-functions-in-parkinson-s-disease
#15
Asya Ozkizilcik, Aruna Sharma, Dafin F Muresanu, José V Lafuente, Z Ryan Tian, Ranjana Patnaik, Herbert Mössler, Hari S Sharma
Previous studies from our laboratory show that intraperitoneal injections of 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP, 20 mg/kg) daily within 2-h intervals for 5 days in mice induce Parkinson's disease (PD)-like symptoms on the 8th day. A significant decrease in dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) along with a marked decrease in the number of tyrosine hydroxylase (TH)-positive cells in the substantia nigra pars compacta (SNpc) and striatum (STr) confirms the validity of this model for studying PD...
September 5, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28847022/attenuation-of-morphine-induced-tolerance-and-dependence-by-pretreatment-with-cerebrolysin-in-male-rats
#16
Hamed Ghavimi, Sara Darvishi, Saeed Ghanbarzadeh
Background Dependence and tolerance to morphine are major problems which limit its chronic clinical application. Purpose This study was aimed to investigate the attenuation effect of Cerebrolysin, a mixture of potent growth factors (BDNF, GDNF, NGF, CNTF etc,), on the development of Morphine-induced dependence and tolerance. Methods Male Wistar rats were selected randomly and divided into different groups (n=8) including: a control group, groups received additive doses of morphine (5-25 mg/kg, ip, at an interval of 12 h until tolerance completion), and groups pretreated with Cerebrolysin (40, 80 and 160 mg/kg, ip, before morphine administration)...
August 28, 2017: Drug Research
https://www.readbyqxmd.com/read/28844104/co-administration-of-tio2-nanowired-mesenchymal-stem-cells-with-cerebrolysin-potentiates-neprilysin-level-and-reduces-brain-pathology-in-alzheimer-s-disease
#17
Hari Shanker Sharma, Dafin Fior Muresanu, José Vicente Lafuente, Ranjana Patnaik, Z Ryan Tian, Asya Ozkizilcik, Rudy J Castellani, Herbert Mössler, Aruna Sharma
Neprilysin (NPL), the rate-limiting enzyme for amyloid beta peptide (AβP), appears to play a crucial role in the pathogenesis of Alzheimer's disease (AD). Since mesenchymal stem cells (MSCs) and/or cerebrolysin (CBL, a combination of neurotrophic factors and active peptide fragments) have neuroprotective effects in various CNS disorders, we examined nanowired delivery of MSCs and CBL on NPL content and brain pathology in AD using a rat model. AD-like symptoms were produced by intraventricular (i.c.v.) administration of AβP (1-40) in the left lateral ventricle (250 ng/10 μl, once daily) for 4 weeks...
August 26, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28840482/nanodelivery-of-cerebrolysin-and-rearing-in-enriched-environment-induce-neuroprotective-effects-in-a-preclinical-rat-model-of-parkinson-s-disease
#18
C Requejo, J A Ruiz-Ortega, H Cepeda, A Sharma, H S Sharma, A Ozkizilcik, R Tian, H Moessler, L Ugedo, J V Lafuente
Rearing in enriched environment (EE) improves the recuperation in animal models of Parkinson's disease (PD). Administration of TiO2-nanowired cerebrolysin (CBL) could represent an additional strategy to protect or repair the nigrostriatal system. This study aims to explore morphofunctional and biochemical changes in a preclinical stage of PD testing the synergistic efficiency of combining both strategies, housing in EE, and nanodelivery of CBL. Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment)...
August 24, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28747461/hope-dies-last-evidence-again-fails-to-support-a-neuroprotectant-cerebrolysin-for-acute-ischemic-stroke
#19
EDITORIAL
Daniel Bereczki
No abstract text is available yet for this article.
September 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28707130/safety-and-efficacy-of-cerebrolysin-in-motor-function-recovery-after-stroke-a-meta-analysis-of-the-cars-trials
#20
Alla Guekht, Johannes Vester, Wolf-Dieter Heiss, Eugene Gusev, Volker Hoemberg, Volker W Rahlfs, Ovidiu Bajenaru, Bogdan O Popescu, Edith Doppler, Stefan Winter, Herbert Moessler, Dafin Muresanu
This meta-analysis combines the results of two identical stroke studies (CARS-1 and CARS-2) assessing efficacy of Cerebrolysin on motor recovery during early rehabilitation. Cerebrolysin is a parenterally administered neuropeptide preparation approved for the treatment of stroke. Both studies had a prospective, randomized, double-blind, placebo-controlled design. Treatment with 30 ml Cerebrolysin once daily for 3 weeks was started 24-72 h after stroke onset. In addition, patients participated in a standardized rehabilitation program for 21 days that was initiated within 72 h after stroke onset...
July 13, 2017: Neurological Sciences
keyword
keyword
114120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"